Dopegyt en es it fr

Dopegyt Brand names, Dopegyt Analogs

Dopegyt Brand Names Mixture

  • No information avaliable

Dopegyt Chemical_Formula


Dopegyt RX_link

Dopegyt fda sheet

Dopegyt FDA

Dopegyt msds (material safety sheet)

Dopegyt MSDS

Dopegyt Synthesis Reference

No information avaliable

Dopegyt Molecular Weight

1270.28 g/mol

Dopegyt Melting Point

No information avaliable

Dopegyt H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Dopegyt State


Dopegyt LogP

No information avaliable

Dopegyt Dosage Forms

Powder for solution (for injection)

Dopegyt Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Dopegyt Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Dopegyt Absorption

No information avaliable

Dopegyt side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Dopegyt Patient Information

No information avaliable

Dopegyt Organisms Affected

Aspergillis, Candida and other fungi